Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Ribosomal protein S6 kinase 70kDa polypeptide 1 (RPS6KB1; S6K1)

June 23, 2016 7:00 AM UTC

In vitro and mouse studies suggest inhibiting RPS6KB1 could help treat AML and other hematologic malignancies. In a human AML cell line, an RPS6KB1 inhibitor tool compound decreased cell growth compared with vehicle. In a xenograft mouse model of AML, the inhibitor increased survival. Next steps could include testing RPS6KB1 inhibitors in additional models of AML and other hematologic malignancies. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article